ClinicalTrials.gg
RecruitingNCT07346144ADePTUpdated Oct 23, 2026

Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma

A Phase 1/2 interventional study of TGX-007 and Valaciclovir in Glioblastoma (GBM), High Grade Gliomas and Recurrent Glioblastoma, sponsored by Trogenix ltd. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Trogenix ltd · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
68
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,303 studies in Glioblastoma with a site in United States — 194 open to participants now, 324 under way, 16 of them phase 3. Glioblastoma · United States.

Planned enrollment
257th of 1,156
68 · median 33
Started
2026
with 55 others
Phase 1/2
190 of 1,303
32 open now
Primary completion
2030-03
later than 283 of 322 live
Registered
1,253rd of 1,303
by date

Among the 1,303 studies in Glioblastoma with a site in United States, this one is the 257th largest by planned enrollment of the 1,156 interventional ones that give a count, is one of 56 that started in 2026, is one of 190 in phase 1/2, reaches primary completion later than 283 of the 322 other live ones, and was the 1,253rd registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

194 of the 1,303 studies in Glioblastoma with a site in United States are open now. Recruiting first, the newest first:

189 more — sign in →

All 194 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,303 studies in Glioblastoma with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to first define the Safety and Optimal Biological Dose (OBD) of study drug TGX-007 and to then further investigate the safety and efficacy in patients with newly diagnosed or recurrent Glioblastoma.

TGX-007 is a gene therapy drug delivered by a harmless adeno-associated virus (AAV) vector which delivers two combined therapeutic payloads to enable killing of proliferative cells and activation of an anti-tumour immune response. One is herpes simplex virus thymidine kinase (HSV-tk), which converts the pro-drug valaciclovir into an active drug that can kill tumour cells and the other is interleukin 12 (IL-12), which activates the body's immune system to recognise and fight the tumour.

Patients newly diagnosed with glioblastoma suitable for standard of care surgery and chemoradiotherapy or patients with recurrent glioblastoma suitable for further surgery may be eligible for the study. Patients will receive TGX-007 by a direct intratumoural injection and will then take the pro-drug valacyclovir orally for up to 21 days before proceeding to standard of care surgery.

The study is split into two phases. Phase I will treat patients at different dose levels of TGX-007 to identify the Optimal Biological Dose that will be used to further expand the study into Phase II. Phase II will expand the number of patients treated at the selected OBD to investigate how effective TGX-007 is at treating newly diagnosed and recurrent GBM.

Approximately 68 people aged 18-70 will take part in the study.

03

Conditions studied

  • Glioblastoma (GBM)
  • High Grade Gliomas
  • Recurrent Glioblastoma
  • Newly Diagnosed Glioblastoma

Browse trials for

Keywords

  • Glioblastoma
  • Immunotherapy
  • Gene Therapy
  • AAV
  • HSV-tk
  • IL-12
  • TGX-007
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18-70 years
  • performance status ≥70
  • Newly diagnosed patients: Unifocal, unilateral high-grade glioma based on MRI
  • Recurrent patients: First radiological progression (as determined by the multidisciplinary team [MDT]) of GBM previously treated with standard care surgery and chemoradiotherapy. Patients must have a prior confirmed histological/molecular diagnosis of GBM
  • Newly diagnosed patient: suitable for six weeks of chemoradiotherapy followed by six months of adjuvant temozolomide (Stupp protocol)
  • Debulking surgery is indicated for optimal patient care
  • Able to swallow oral medication
  • Willing to avoid
  • Adequate organ function
  • Female patients of must have a negative serum pregnancy test within 7 days prior to Day 0.
  • All patients must agree to practice true abstinence or to use highly effective
  • Patient is willing and able to give for participation in the study

Exclusion criteria

Exclusion Criteria:

  • Patient who is pregnant, lactating or planning pregnancy during the course of the study
  • Immunodeficiency or active auto-immune disease requiring systemic therapy.
  • Active viral, bacterial or fungal infection requiring concurrent antivirals or antibiotics within 7 days of surgery
  • within 28 days prior to Day 0
  • Use of or immune modulatory medicines within 28 days prior to Day 0
  • History of tuberculosis infection or chest x-ray or computed tomography (CT) chest showing radiological evidence of previous tuberculosis infection
  • Received previous treatment with a gene therapy
  • Significant history of a central nervous system disorder that, in the opinion of the Investigator, would preclude enrolment
  • Major surgery within 28 days prior to Day 0. A stereotactic is permitted
  • Known or to valaciclovir, gadolinium, or any for TGX-007
  • Contraindication to MRI with gadolinium
  • Any condition expected to interfere with the intended timing of debulking surgery
  • Previous non-glioma cancer within 3 years (other than treated squamous/basal cell skin cancer, treated early-stage cervical cancer or treated/biochemically stable, organ confined prostate cancer)
  • Any other significant disease or disorder which, in the opinion of the Investigator, may put the patient at risk because of participation in the study or may influence the results of the study or the patient's ability to participate in the study
  • Patients who have participated in another research study involving an product in the past 12 weeks or 5 half-lives of the product
  • Any psychological, familial, sociological, or geographical consideration potentially hampering compliance with the study protocol and follow up schedule; these conditions should be discussed with the patient before registration in the study
  • Unwilling to allow their general practitioner, if appropriate, to be notified of participation in the study

Newly diagnosed patients only:

  • Any prior therapy for glioma
  • Intended use of tumour treating fields

Recurrent patients only:

  • Prior toxicities from anti-cancer agents or radiotherapy which have not recovered to ≤Grade 1 severity
  • Intended use of tumour treating fields
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    Dose Finding

    Dose escalation (with dose levels -1, 1, 2)

    Drug: TGX-007 · Drug: Valaciclovir

  • Experimental
    Newly Diagnosed Expansion

    Expansion in Newly Diagnosed High Grade Glioma patients at the Optimal Biological Dose.

    Drug: TGX-007 · Drug: Valaciclovir

  • Experimental
    Recurrent Glioblastoma Expansion

    Expansion in recurrent glioblastoma patients at the Optimal Biological Dose.

    Drug: TGX-007 · Drug: Valaciclovir

Interventions

  • DrugTGX-007

    TGX-007 administered as single intratumoural injection

  • DrugValacyclovirStudies of ValacyclovirValacyclovir pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral valaciclovir administered 3 times daily for 14 - 21 days

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of TGX-007 when administered to patients with newly diagnosed HGG or recurrent GBM and to identify the OBD

    Incidence of AEs/SAEs, incidence of DLT within 28 days of TGX-007 administration at each dose level, and incidence of HSV-tk mRNA expression, or equivalent, in tissue

    Time frame: Day 0 (TGX-007 injection) to 28 days post administration of TGX-007

  2. Overall Survival rate of patients with newly diagnosed HGG or recurrent GBM treated with TGX-007

    Overall Survival at 18 months (newly diagnosed patients) and 6 months (recurrent patients).

    Time frame: Day 0 (TGX-007 injection) to 18 months (newly diagnosed); Day 0 (TGX-007 injection) to 6 months (recurrent patients)

Secondary outcomes

  1. Overall Survival

    Median OS and OS up to 5 years by Kaplan-Meier analysis.

    Time frame: Baseline to 5 year follow up

  2. Viral shedding in body fluids following delivery of TGX-007.

    Detection of vector genomes by droplet digital polymerase chain reaction (ddPCR) in patient samples

    Time frame: Baseline until 3 consecutive negative samples, assessed up to 5 years post treatment.

  3. Progression-free survival (PFS) of patients with newly diagnosed HGG or recurrent GBM treated with TGX-007.

    PFS as determined by the Investigator

    Time frame: Date of surgery to the earliest date progression is documented or death from any cause, measured out to 5 years post surgery

  4. Objective response rate (ORR) of patients with newly diagnosed HGG or recurrent GBM treated with TGX-007.

    ORR on pre-operative MRI per Response Assessment in Neuro-Oncology 2.0 (RANO 2.0) criteria.

    Time frame: Baseline to 21 days

  5. Assess the safety and tolerability of TGX-007 when administered to patients with newly diagnosed HGG or recurrent GBM

    Incidence of AEs/SAEs.

    Time frame: Baseline to 5 year follow up

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Mar 2030, 47 months after the start.

Of 52 industry-sponsored phase 1/2 interventional studies under Glioblastoma, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 75. This study's planned 47 months is below that.

Counting every sponsor, half of 137 studies reached it within 66 months; a quarter within 45 and three quarters within 102.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2026
First posted
Jan 16, 2026
StartActual
Apr 21, 2026
Primary completionEst.
Mar 2030
CompletionEst.
Sep 2033
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Site contacts
Changed at 1 site. See the sites
Show the site
  • Ohio State University Hospital · Columbus, United StatesContact H•••@osumc.edu→C•••@osumc.edu
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Ohio State University Hospital · Columbus, United StatesContact H•••@osumc.edu→C•••@osumc.edu
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07346144
Lead sponsor
Trogenix ltd
Responsible party
Sponsor
First posted
Jan 16, 2026
Start date
Apr 21, 2026
Primary completion
Mar 2030 (estimated)
Completion
Sep 2033 (estimated)
Last update
Oct 23, 2026

Study contacts

Project Management
Contact
Contact@trogenix.com
+44131 287 5960

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion